Work

Population pharmacokinetics and exposure–response analysis of acalabrutinib in patients with untreated mantle cell lymphoma in the ECHO trial

Year: 2026
Type: article
Abstract: AIMS: The phase 3 ECHO trial demonstrated superior progression-free survival (PFS) with acalabrutinib plus bendamustine-rituximab (BR) versus placebo plus BR in treatment-naive (TN) mantle cell lymphoma (MCL). This analysis characterizes the pharmacokinetic (PK) profile of acalabrutinib and ACP-5862 (active metabolite) when administered with BR and evaluates exposure-response (efficacy/safety) relationships based on ECHO data. METHODS: In ECHO, patients aged ≥65 years with TN MCL received BR plus acalabrutinib or placebo. Acalabrutinib (100 mg twice daily) or placebo was administered at study start until progressive disease or unacceptable toxicity. A pooled population PK analysis dataset included 975 patients for acalabrutinib and 580 patients for ACP-5862 from ECHO plus 10 clinical trials. Exposure-response analyses examined associations between exposure and PFS, best overall response (BOR), and adverse events (AEs) from ECHO. RESULTS: Population PK analysis showed that demographics (age, body weight, sex, ethnicity, race) and other intrinsic factors (mild or moderate renal impairment; mild or moderate hepatic impairment) had no meaningful effect on acalabrutinib/ACP-5862 exposure. No impact of co-administration with BR was observed on PK exposure. Exposure-efficacy analyses of ECHO data showed a flat relationship between acalabrutinib/ACP-5862 exposure and PFS and BOR. Exposure-safety analyses of ECHO data showed no clinically meaningful correlation between acalabrutinib/ACP-5862 exposure and selected safety outcomes (grade ≥3 AEs and events of clinical interest, AEs leading to dose modifications). CONCLUSION: This analysis supports a fixed 100 mg twice daily acalabrutinib dose, in combination with BR, as well-tolerated and efficacious in treatment of patients with TN MCL.
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,780
Funder: AstraZeneca
OpenAlex ID: W7235988531
FWCI:
Cites: 18
Cited by:
Related to: 10